A clinical prediction model for infusion-related reactions to rituximab in patients with B cell lymphomas-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A clinical prediction model for infusion-related reactions to rituximab in patients with B cell lymphomas

Published:2017-01-31 Issue:2 Volume:39 Page:380-385
ISSN:2210-7703
Container-title:International Journal of Clinical Pharmacy
language:en
Short-container-title:Int J Clin Pharm

Author:

Hayama Tatsuya,Miura Katsuhiro,Uchiike Akihiro,Nakagawa Masaru,Tsutsumi Daisuke,Sakagami Masashi,Yoshida Yoshikazu,Takei Masami

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmaceutical Science,Pharmacology,Toxicology,Pharmacy

Link

http://link.springer.com/content/pdf/10.1007/s11096-017-0429-3.pdf

Reference17 articles.

1. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–42.

2. Byrd JC, Murphy T, Howard RS, Lucas MS, Goodrich A, Park K, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol. 2001;19:2153–64.

3. Hainsworth JD, Litchy S, Burris HA 3rd, Scullin DC Jr, Corso SW, Yardley DA, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin’s lymphoma. J Clin Oncol. 2002;20:4261–7.

4. Schwartzberg LS, Stepanski EJ, Fortner BV, Houts AC. Retrospective chart review of severe infusion reactions with rituximab, cetuximab, and bevacizumab in community oncology practices: assessment of clinical consequences. Support Care Cancer. 2008;16:393–8.

5. Schwartzberg LS, Stepanski EJ, Walker MS, Mathias S, Houts AC, Fortner BV. Implications of IV monoclonal antibody infusion reaction for the patient, caregiver, and practice: results of a multicenter study. Support Care Cancer. 2009;17:91–8.

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of the inhibitory effects between bepotastine and diphenhydramine on rituximab-induced infusion-related reactions: A single-center retrospective study;2024-09-11

2. Association between the incidence of infusion-related reactions by obinutuzumab and the dose of corticosteroid as premedication: A multicenter retrospective cohort study;2024-09-10

3. Infusion-Related Reactions Subsequent to Avelumab, Durvalumab, and Atezolizumab Administration: A Retrospective Observational Study;Clinics and Practice;2024-02-23

4. Characteristics and predictors of infusion-related reactions to rituximab in patients with B-cell non-Hodgkin lymphoma;Journal of Chemotherapy;2023-10-20

5. Efficacy of low-dose rituximab in minimal change disease and prevention of relapse;BMC Nephrology;2023-04-26

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3